BioCardia Inc.

1.92
0.01 (0.52%)
At close: Apr 17, 2025, 3:59 PM
1.89
-1.55%
After-hours: Apr 17, 2025, 07:50 PM EDT

Company Description

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases.

Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease.

The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure.

In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths.

The company is based in Sunnyvale, California.

BioCardia Inc.
BioCardia Inc. logo
Country United States
IPO Date Nov 13, 1996
Industry Biotechnology
Sector Healthcare
Employees 17
CEO Dr. Peter A. Altman Ph.D.

Contact Details

Address:
320 Soquel Way
Sunnyvale, California
United States
Website https://www.biocardia.com

Stock Details

Ticker Symbol BCDA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000925741
CUSIP Number 09060U507
ISIN Number US09060U5074
Employer ID 23-2753988
SIC Code 2836

Key Executives

Name Position
Dr. Peter A. Altman Ph.D. Chief Executive Officer, President & Director
David McClung Chief Financial Officer
Edward M. Gillis Senior Vice President of Devices

Latest SEC Filings

Date Type Title
Apr 17, 2025 4 Filing
Apr 15, 2025 8-K Current Report
Apr 14, 2025 4 Filing
Apr 11, 2025 8-K Current Report
Apr 08, 2025 4 Filing
Apr 07, 2025 4 Filing
Apr 04, 2025 4 Filing
Apr 04, 2025 424B5 Filing
Apr 04, 2025 8-K Current Report
Apr 03, 2025 4 Filing